{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064435","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.297296+00:00","generated_at":"2026-05-22T12:44:03.260444+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR Therapeutics Q1 2025 net loss $136M; CTX310 Phase 1 shows up to 82% TG reduction","bullets":["Net loss of $136.0M in Q1 2025, compared to $116.6M in Q1 2024; cash & equivalents $1.86B.","CTX310 Phase 1 data: dose-dependent reductions in LDL (up to 81%) and TG (up to 82%) with well-tolerated safety.","CASGEVY: >65 authorized treatment centers activated; ~90 patients with first cell collection; new initiations to grow in 2025.","R&D expenses $72.5M, G&A $19.3M; collaboration expense net $57.5M (driven by CASGEVY and in vivo HSC editing).","CTX320 (Lp(a)) dose escalation ongoing with update expected Q2 2025; CTX112/CTX131 CAR T updates mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064435","json":"https://secwatch.observer/filing/0000950170-25-064435.json","markdown":"https://secwatch.observer/filing/0000950170-25-064435.md","text":"https://secwatch.observer/filing/0000950170-25-064435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025064435/0000950170-25-064435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025064435/crsp-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:44:03.260444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}